Qatar, Kuwait, Oman and Bahrain pharmaceutical markets: size, growth and outlook 2026–2032

The four smaller GCC pharma markets buy through central tenders and import almost everything. Published estimates normalised to 2025 range from USD 184 m to USD 4.2 bn; the Consulting Wallah central estimate is USD 7.5 bn, growing at about 7% a year to USD 12.0 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by growth in biologics and specialty medicines for chronic/complex disease (Qatar); e-prescribing, telemedicine and e-health adoption; government push for domestic manufacturing and essential-medicine self-sufficiency (Oman OPAZ incentives, Qatar).

Context that matters for buyers and suppliers: Gulf Joint Procurement (GCC Health Council) programme traces to Feb 1976; covers 6 GCC health ministries, >20 public hospitals and ~18 material categories; tender cycle ~4 months. Generic drugs accounted for >60% of GCC pharmaceutical sales in 2023; Saudi Arabia holds 46.5% of GCC market. Kuwait imports ~90% of its pharmaceuticals; KSPICO is the sole local manufacturer. Oman offers up to 30-year tax exemptions, 100% foreign ownership, 50-year usufruct and 10% price preference for national products in government tenders.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 184 m–USD 4.2 bn; differences are mostly scope.

Included: prescription and OTC pharmaceuticals, biologics and vaccines across hospital, retail and government channels. Excluded: medical devices, nutrition. Figures at ex-manufacturer vs retail prices differ by 20–40%, which explains part of the published range.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Gulf Joint Procurement (GCC Health Council) programme traces to Feb 1976; covers 6 GCC health ministries, >20 public hospitals and ~18 material categories; tender cycle ~4 months (Supply Chain Digital)
• Generic drugs accounted for >60% of GCC pharmaceutical sales in 2023; Saudi Arabia holds 46.5% of GCC market (Ken Research)
• Kuwait imports ~90% of its pharmaceuticals; KSPICO is the sole local manufacturer (AGBI / BMI / KDIPA)
• Oman offers up to 30-year tax exemptions, 100% foreign ownership, 50-year usufruct and 10% price preference for national products in government tenders (Oman Observer / OPAZ)
• Oman's National Pharmaceutical Industries exports to >50 countries (Oman Observer)
• Bahrain NHRA Pharmaceutical Products Regulation (2021) covers marketing authorisation, GMP, bioequivalence and post-marketing surveillance; prescription drugs dominate and hospitals are leading end-user (Ken Research)
• Qatar prescription drugs ~75% of market; hospital pharmacies ~28% of distribution (MarkNtel Advisors)
• Gulf Health Council drug registration timelines exceed 12 months (Ken Research)

Where the GCC and India sit

• Qatar: USD 4.20 bn (2025) — IMARC Group
• Qatar: USD 532 mn (as published; unit ambiguity) (2025) — MarkNtel Advisors
• Kuwait: USD 2.9 bn (forecast) (2027) — BMI via AGBI
• Oman: USD 752.4 mn (2024) — OPAZ via Oman Observer
• Oman pharma imports: USD 670.3 mn (up from USD 565 mn in 2021) (2023) — Oman Observer
• Bahrain: USD 170 mn (2024) — Ken Research

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: oman free-zone pharma investments (>USD 600 mn in Salalah, ~USD 600 mn Khazaen, >USD 100 mn Madayn) with 10-20% advance purchase agreements; generic and penicillin manufacturing in Oman (Sohar penicillin project); qatar CAR-T / cell therapy platform (Sidra Medicine) and health accelerators.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers: registration and a strong local agent decide access; serialisation and GMP inspection readiness shorten the path; localisation stories win public tenders.
• Hospital leaders: class-level lots, biosimilars and IV→oral switch programmes are the three savings levers; the drug repository lists the class members.
• Distributors: buyers increasingly want data (catalogue, serialisation events, fill rates) as much as product.

1. IMARC Group, Qatar Pharmaceutical Market Size, Share, Growth 2026-2034 — imarcgroup.com
2. MarkNtel Advisors, Qatar Pharmaceuticals Market press release — marknteladvisors.com
3. AGBI, Kuwait's pharmaceutical plan may need a shot in the arm — agbi.com
4. Oman Observer, Oman pharmaceutical market to hit $1.24 billion — omanobserver.om
5. BlueWeave Consulting, Oman Pharmaceuticals Market Size Set to Reach USD 474 Million by 2031 — blueweaveconsulting.com
6. Ken Research, Bahrain Pharmaceuticals Market Report 2025-2030 — kenresearch.com
7. Ken Research, GCC Pharmaceutical Market Report 2025-2030 — kenresearch.com
8. Supply Chain Digital, Gulf Joint Procurement programme helps to standardise medicine supply in the GCC — supplychaindigital.com
9. IMARC Group (2026-07) — USD 4.20 bn (USD 4,200.64 mn) (2025) to USD 10.61 bn (2034), CAGR 10.85% (2026-2034); scope: Country: Qatar pharmaceutical market; Report SR112026A44349 — source
10. OPAZ / The Duqm Economist via Oman Observer (2026-07) — USD 752.4 mn (2024) to USD 1.24 bn (2031), CAGR 7.4%; scope: Country: Oman pharmaceutical market — source
11. Ken Research (2025-12) — USD 170 mn (2024) to — (2030), CAGR —; scope: Country: Bahrain pharmaceuticals market; generics ~60% of sales; product code KRAE0947 — source
12. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
13. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.